Prescription medicine
Nifurtimox Brand names: Lampit
Nifurtimox (Lampit) is a prescription medicine with an FDA approval on record since 2020. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the nifurtimox FDA label on DailyMed (effective March 3, 2026, Bayer HealthCare Pharmaceuticals Inc.); the NDA 213464 record on Drugs@FDA; every nifurtimox label on DailyMed.
Highlights of the record
FDA label of March 3, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageLAMPIT is indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi [see Clinical Studies ( 14 )].
Forms and strengths
- 30 mg
- 120 mg
Film-coated tablet.
On the market
- Earliest approval on file
- August 6, 2020 Lampit, Bayer Healthcare; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 25 through July 30, 2026
What is nifurtimox used for?
From the label: indications and usageLAMPIT is indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi [see Clinical Studies ( 14 )]. LAMPIT is a nitrofuran antiprotozoal, indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi.
Source: FDA drug label (LAMPIT), Bayer HealthCare Pharmaceuticals Inc., effective March 3, 2026 (SPL set 90d09714-a8b1-4696-8ada-f99dc54d0721), via openFDA; the full label on DailyMed
Is there a generic for nifurtimox (Lampit)?
No generic nifurtimox is approved (Drugs@FDA, October 8, 2026).
- 2020 earliest approval on file
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the nifurtimox label say about other medicines?
The nifurtimox label names no other medicine on this site. The labels of 1 other medicine name nifurtimox. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
Source: FDA drug label (LAMPIT), Bayer HealthCare Pharmaceuticals Inc., effective March 3, 2026 (SPL set 90d09714-a8b1-4696-8ada-f99dc54d0721), via openFDA; the full label on DailyMed
What do FAERS reports show for nifurtimox?
The FDA Adverse Event Reporting System holds 25 reports that list nifurtimox among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 3 are coded as a death and 11 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Nifurtimox side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other